4-((3'-fluoro)phenoxy)benzonitrile | 877149-18-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-((3'-fluoro)phenoxy)benzonitrile
• 英文别名: 4-(3-Fluorophenoxy)benzonitrile
• CAS: 877149-18-3
• 化学式: C₁₃H₈FNO
• mdl: MFCD08559040
• 分子量: 213.211
• InChiKey: HPBQAEPAVNQRDT-UHFFFAOYSA-N

物化性质

• 熔点：
  67-69 °C
• 沸点：
  322.6±27.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  33
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-((3'-fluoro)phenoxy)benzonitrile 在 水 、 sodium hydroxide 作用下， 反应 5.0h， 以11.61 g的产率得到4-(3-fluorophenoxy)benzoic acid
  参考文献：
  名称：

  [EN] INHIBITORS OF BRUTON'S TYROSINE KINASE
  [FR] INHIBITEURS DE TYROSINE KINASE DE BRUTON

  摘要：

  公开号：

  WO2013010136A3
• 作为产物：
  描述：

  3-氟苯酚 、 4-溴苯腈 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 以56%的产率得到4-((3'-fluoro)phenoxy)benzonitrile
  参考文献：
  名称：

  Merging the Structural Motifs of Functionalized Amino Acids and α-Aminoamides: Compounds with Significant Anticonvulsant Activities

  摘要：

  Functional amino acids (FAAs) and alpha-aminoamides (AAAs) are two classes of antiepileptic drugs (AEDs) that exhibit pronounced anticonvulsant activities. We combined key structural pharmacophores present in FAAs and AAAs to generate a new series of compounds and document that select compounds exhibit activity superior to either the prototypical FAA (lacosamide) or the prototypical AAA (safinamide) in the maximal electroshock (MES) seizure model in rats. A representative compound, (R)-N-4'-((3 ''-fluoro)benzyloxy)benzyl 2-acetamido-3-methoxypropionamide ((R)-10), was tested in the MES (mice, ip), MES (rat, po), psychomotor 6 Hz (32 mA) (mice, ip), and hippocampal kindled (rat, ip) seizure tests providing excellent protection with ED50 values of 13, 14, similar to 10 mg/kg, and 12 mg/kg, respectively. In the rat sciatic nerve ligation model (ip), (R)-10 (12 mg/kg) provided an 11.2-fold attenuation of mechanical allodynia. In the mouse biphasic formalin pain model (ip), (R)-10 (15 mg/kg) reduced pain responses in the acute and the chronic inflammatory phases.

  DOI：

  10.1021/jm100185c

文献信息

• [EN] ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS<br/>[FR] COMPOSES A BASE D'ISOINDOLONE ET LEUR UTILISATION COMME POTENTIALISATEURS DU RECEPTEUR METABOTROPIQUE DU GLUTAMATE
  申请人：ASTRAZENECA AB

  公开号：WO2006020879A1

  公开（公告）日：2006-02-23

  The present invention is directed to compounds of formula (I), wherein R1 is a ring and n is a number from 1 to 8. The invention also relates to use of the compounds in therapy as metabotropic glutamate receptor modulators, particularly in neurological and psychiatric disorders.

  本发明涉及式(I)的化合物，其中R1是一个环，n是1到8之间的数字。该发明还涉及将这些化合物用于治疗作为代谢型谷氨酸受体调节剂，特别是在神经系统和精神疾病中的用途。
• (4-Phenoxyphenyl)tetrazolecarboxamides and related compounds as dual inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL)
  作者：Angela Holtfrerich、Walburga Hanekamp、Matthias Lehr

  DOI：10.1016/j.ejmech.2013.01.050

  日期：2013.5

  Inhibitors of the enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), the principle enzymes involved in the degradation of endogenous cannabinoids like anandamide and 2-arachidonoylglycerol, have potential utility in the treatment of several disorders including pain, inflammation and anxiety. In the present study, the effectivity and selectivity of eight known FAAH and MAGL

  脂肪酸酰胺水解酶（FAAH）和单酰基甘油脂酶（MAGL）的抑制剂是参与降解内源性大麻素（如anandamide和2-arachidonoylglycerol）的主要酶，在治疗包括疼痛，炎症和焦虑症在内的多种疾病中具有潜在的用途。 。在本研究中，通过体外测定了八种已知的FAAH和MAGL抑制剂对适当酶的抑制作用的选择性和有效性。在可比较的条件下工作的分析方法。由于许多已知的FAAH和MAGL抑制剂仅由结合了杂环系统的亲脂性支架组成，因此，通过将不同的杂环结构连接到相同的亲脂性骨架（即4-苯氧基苯）上，评估了它们对酶抑制的作用。在此研究中合成的最具活性的化合物之一是N，N-二甲基-5-（4-苯氧基苯基）-2 H-四唑-2-羧酰胺（16）（IC 50 FAAH：0.012μM; IC 50MAGL：0.028μM）。该抑制剂在亲脂性4-苯氧基苯基区域被系统修饰。结构-活性关系研究表明，通过用3-
• Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
  申请人：Clayton Joshua

  公开号：US20090275578A1

  公开（公告）日：2009-11-05

  The present invention is directed to compounds of formula I: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.

  本发明涉及式I的化合物：其中R1，R2，R3，R4，R5，R6，R7，R8，R9和n在描述中定义为式I。本发明还涉及制备该化合物的过程，以及用于制备的新中间体，含有该化合物的制药组合物，以及在治疗中使用该化合物。
• Novel N-Benzylamide Substituted Derivatives of 2-(Acylamido)acetic Acid and 2-(Acylamido)propionic Acids: Potent Neurological Agents
  申请人：Kohn Harold L.

  公开号：US20120232015A1

  公开（公告）日：2012-09-13

  A first aspect of the invention is a compound (sometimes also referred to herein as an “active agent” or “active compound”) of Formula Ia, or more particularly Formula Ib, or a pharmaceutically acceptable salt or prodrug thereof. Compositions thereof and methods of using the same (e.g. for the treatment of a neurological disease) are also described.

  本发明的第一个方面是公式Ia的化合物（有时也在此处称为“活性剂”或“活性化合物”）或更具体地为公式Ib的化合物，或其药物可接受的盐或前药。还描述了其组成物和使用方法（例如，用于治疗神经系统疾病）。
• INHIBITORS OF BRUTON'S TYROSINE KINASE
  申请人：CHEN Wei

  公开号：US20130018032A1

  公开（公告）日：2013-01-17

  Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.

  本文描述了激酶抑制剂化合物、合成这种抑制剂的方法，以及使用这种抑制剂治疗疾病的方法。此外，本文还描述了确定蛋白质（包括激酶）适当抑制剂的方法、测定和系统。